DARZALEX FASPRO is the First and Only Treatment Approved by the U.S. FDA for Patients With High-risk Smoldering Multiple Myeloma
November 07, 2025
November 07, 2025
RARITAN, New Jersey, Nov. 7 -- Johnson and Johnson Innovative Medicine issued the following news release on Nov. 6, 2025:
* * *
DARZALEX FASPRO(R) is the first and only treatment approved by the U.S. FDA for patients with high-risk smoldering multiple myeloma
Phase 3 AQUILA study showed DARZALEX FASPRO(R) significantly reduced the risk of progression to active multiple myeloma or death by 51 percent compared to active monitoring
Landmark approv . . .
* * *
DARZALEX FASPRO(R) is the first and only treatment approved by the U.S. FDA for patients with high-risk smoldering multiple myeloma
Phase 3 AQUILA study showed DARZALEX FASPRO(R) significantly reduced the risk of progression to active multiple myeloma or death by 51 percent compared to active monitoring
Landmark approv . . .